The government-sponsored Trial to Assess Chelation Therapy (TACT)—is finally over and the results are highly promising! Though, the results no doubt anger some of the anti-alternative medicine crusaders who fought to get the ten-year trial cancelled. TACT was the first large-scale, multicenter study designed to determine the safety and efficacy of EDTA chelation therapy for individuals with coronary heart disease. Overall, the chelation treatments reduced heart attacks, strokes, deaths, hospitalization for chest pain or need for an artery-opening procedure.
Mount Sinai Medical Center studies chelation therapy in heart attack survivors
The randomized, blinded, placebo-controlled study was based out of Mount Sinai Medical Center and involved 1,708 heart attack survivors. Participants were randomly assigned to receive 40 weekly infusions of either the standard EDTA chelation solution or placebo delivered intravenously (through the veins). The patients were followed for an average of four years. Ethylenediamine tetraacetic acid, or EDTA, is a synthetic amino acid that is approved by the FDA for removal of toxic metal ions such as lead. Repeated EDTA administration is thought to reduce atherosclerotic plaque and other mineral deposits throughout the cardiovascular system, especially the hardened arteries around the heart.
Although not yet published, the results of this clinical trial were presented at the American Heart Association’s 2012 Annual Scientific Sessions on November 4th. The study’s lead researcher, Dr. Gervasio Lamas, MD, is the Chairman of Medicine at Mount Sinai Medical Center and Chief of the Columbia University Division of Cardiology at Mount Sinai Medical Center.
Chelation therapy helps prevent heart attacks, strokes, and death in those with heart disease
Dr. Lamas explained how chelation therapy showed benefit for the prevention of heart attack, stroke and death in patients with existing coronary artery disease. “There is a significant reduction in the primary endpoint of death, myocardial infarction, stroke, coronary revascularization, or hospitalization for angina, with EDTA chelation compared to placebo,” said Dr. Lamas in his presentation.
Overall, those getting the EDTA chelation had 18% fewer cardiovascular complications than those in the placebo group. Those with diabetes did even better; they had a 39% reduction in deaths, hearts attacks, strokes, hospitalization for chest pain, and medical procedures to restore normal blood flow to the heart.
Furthermore, Dr. Lamas and the other researchers told the audience at the American Heart Association conference that the therapy appeared safe and was well tolerated, despite what some opponents claim.
Chelation therapy may treat heart disease by pulling calcium from arterial plaques
In 2007, over 100,000 patients in the US underwent EDTA chelation therapy. Exactly how it works to reduce deaths and cardiovascular complications in those with heart disease and atherosclerosis is not known. Chelating agents are molecules that surround and bind metal ions. EDTA binds and removes metals in the body such as calcium, zinc, iron, copper, lead, arsenic, cadmium, and aluminum. One hypothesis is that by lowering serum calcium during and immediately after a treatment, the release of parathyroid hormone is stimulated. This, in turn, results in the removal of calcium deposits, including those from atherosclerotic plaque. Meanwhile, the removal of heavy metals and excessive iron and copper results in the reduction of free radical production and a decrease in oxidative stress, which is a big contributor to the development of atherosclerotic plaques (Chappell, 1997).
Is EDTA chelation therapy for you?
Today, a small group of integrative physicians all over the world are specially trained in the use of EDTA chelation for the treatment of a wide variety of chronic degenerative diseases associated with vascular problems. If you’ve had a heart attack, are facing possible bypass surgery or angioplasty, if you have diabetes, or if you’ve been told you have atherosclerosis or coronary artery disease, you may be just the right candidate for chelation therapy. You will need to work with a knowledgeable physician who has gone through a training program such as that offered by the American College for Advancement in Medicine (ACAM). EDTA chelation is almost never used alone; it is usually combined with other intravenous nutrients along with nutrition therapies and lifestyle changes, many of which we discuss in our Comprehensive Guide on Natural Cholesterol Control: Achieve Healthy Cholesterol Levels Without Drugs. You can also discover more information on what you need to know about treating high cholesterol without statin drugs when you download the Comprehensive Guide today, Natural Cholesterol Control: Achieve Healthy Cholesterol Levels Without Drugs.
 Chappell LT. Applications of EDTA Chelation Therapy. Alt Med Rev 1997;2(6):426-432).
 Lamas GA. Results of the Trial to Assess Chelation Therapy (TACT) Summary Slide. American Heart Association Scientific Sessions; November 4, 2012.
 Lamas GA. Results of the Trial to Assess Chelation Therapy Audio Presentation. American Heart Association Scientific Sessions; November 4, 2012.
 Lamas GA, Goertz C, Boineau R, Mark et al. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012 Jan;163(1):7-12.